Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications

Reuters
30 Jun
Cuprina Holdings Announces New Clinical Study on Bullfrog Collagen Peptides for Advanced Wound Care and Cosmeceutical Applications

Cuprina Holdings (Cayman) Ltd. has announced progress on several research studies in collaboration with prominent educational institutes focusing on the development of innovative biomedical and cosmeceutical products. The company is exploring the use of collagen peptides derived from American bullfrog skin for diverse applications, including 3D printable wound care dressings and microneedling patches. These studies are conducted in collaboration with the National University of Singapore and the Singapore Institute of Technology. Cuprina is also investigating the production of superior powdered bullfrog collagen peptides for cosmeceuticals. Results from these studies are anticipated to enhance product offerings in wound care and beauty sectors, with ongoing testing to determine their efficacy. Further updates will be provided as research progresses and results become available.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cuprina Holdings (Cayman) Ltd. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-017049), on June 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10